Latest from Clara Ashworth
Deals
Exor (EXOR), the investment vehicle of Italy's Agnelli family, has updated its shareholder agreement with Philips (PHG) to permit it to increase its holding in the Dutch health technology company to as much as 22%, up from a previous…
19 Aug 2026 Deals
Curium, the private equity-backed radiopharmaceutical company, has agreed to acquire Lantheus Holdings (LNTH) for up to $8bn, marking one of the sector's largest transactions as demand for radioactive compounds used in cancer diagnosis and…
14 Aug 2026 Deals
KKR (KKR) has agreed to acquire medical-device manufacturer Integer Holdings (ITGR) in an all-cash transaction valued at approximately $5.7bn, adding a critical supplier to the medtech industry to its expanding healthcare portfolio.
13 Aug 2026 Deals
Supernus Pharmaceuticals (SUPN) and Indivior (INDV) have agreed to merge in an all-stock transaction to form a central nervous system-focused biopharma, the companies announced, combining five growth-stage products and a combined market…
12 Aug 2026 Deals
AstraZeneca (AZN) shares fell sharply after reports emerged of merger talks with US rival Bristol Myers Squibb (BMY), with investors delivering a swift verdict that the British pharmaceutical giant has little need for a deal that would…
10 Aug 2026 Deals
Merck (MRK) has signed voluntary licensing agreements with seven generic drug manufacturers to produce and sell lower-cost versions of its experimental once-monthly oral HIV pill, alimatravir, across 129 low- and lower-middle-income…
7 Aug 2026 Business
Shares of Alnylam Pharmaceuticals (ALNY) hit a 52-week low of $273.03 last month, extending a steep decline that has seen the RNAi drug developer shed nearly 29% of its value since the start of the year and around 13% over the past 12…
7 Aug 2026 Deals
Argenx (ARGX) has agreed to acquire Forte Biosciences (FBRX) for approximately $2.2 billion, adding the experimental autoimmune therapy FB102 to its portfolio.
3 Aug 2026 Deals
AstraZeneca (AZN) has agreed to pay $600 million upfront to license a lung cancer treatment from China's Dizal Pharmaceutical (688192.SS), sending shares in the Shanghai-listed spinoff surging 20 percent.
31 Jul 2026 Business
Insulet (PODD), the maker of the Omnipod wearable insulin patch, has teamed up with mental health app Calm to launch a suite of free mindfulness resources tailored specifically to people living with diabetes, in what the companies describe…
29 Jul 2026 Business
Lonza is boosting payload-linker manufacturing capacity at its Visp, Switzerland site to meet rising demand for antibody-drug conjugates (ADCs), adding new commercial-scale capabilities expected to come online in 2028. The Swiss CDMO also…
23 Jul 2026 Deals
AstraZeneca has signed a collaboration worth up to $1.77 billion with CSPC Pharmaceutical Group to discover and develop experimental medicines for kidney diseases.
22 Jul 2026 Deals
The Aspen Group has dropped plans to sell its urgent care chain WellNow, stepping back from a process that lenders had expected could generate up to $300 million to help reduce the company's debt burden.
21 Jul 2026 Deals
Novartis agreed to acquire UK-based biotech Myricx Bio for up to $1.5 billion, expanding its oncology pipeline through antibody-drug conjugate (ADC) technology.
20 Jul 2026 Deals
Zymeworks (ZYME) has agreed to acquire Theravance Biopharma (TBPH) for $929mn in cash, four months after the Dublin-based drugmaker shut down its research and development operations, cut half its workforce and put itself up for sale.
14 Jul 2026 Deals
AbbVie (ABBV) has agreed to buy Apogee Therapeutics (APGE) for $10.9bn, its largest acquisition in more than five years, as the pharmaceutical group looks to strengthen its pipeline of treatments for inflammatory diseases such as atopic…
8 Jul 2026 Business
Alnylam Pharmaceuticals (ALNY) shares fell to a 52-week low of $282.71 in mid June, just above the yearly trough of $283.10, extending a slide that has knocked more than a quarter off the drugmaker's valuation in 2026.
1 Jul 2026 Business
Artificial intelligence is generating meaningful time savings for healthcare professionals, but the majority of clinicians report that training in the technology remains inadequate, inconsistent or unavailable at their organizations…
24 Jun 2026 Deals
AlzeCure Pharma (ALZCUR) has signed a collaboration and out-licensing agreement with Eli Lilly (LLY) granting the US drugmaker global rights to an Alzheimer's drug candidate in a deal that could exceed $1bn in total value.
22 Jun 2026 Deals
State Bank of India (SBIN) is preparing to join a consortium of global lenders financing Sun Pharmaceutical Industries' (SUNPHARMA) $12bn acquisition of Organon & Co (OGN), committing up to $1bn pending board approval, according to people…
18 Jun 2026